Dexcom CGM

Leading the way to a new standard of care.

Use of a Dexcom Continuous Glucose Monitoring (CGM) System has been shown to lower A1C.1 Studies have also shown that a lower A1C reduces microvascular and macrovascular complications associated with type 1 diabetes mellitus.2,3

20% Reduction in Cardiovascular Risk<sup>*</sup>2

76% Reduction in Retinopathy Risk<sup>†</sup>3

50% Reduction in Kidney Disease Risk3

*Reduction observed during a mean follow-up of 17 years. †Reduction observed during a mean follow-up of 6 years.

Dexcom CGM Reduces Severe Hypoglycemia<sup>‡</sup>4


‡Defined as requiring assistance from another person or resulting in unconciousness

Improved Glycemic Control

CGM use has shown improvements across 29 indices of glycemic control and glycemic variability,5 and lowers A1C and risk of hypoglycemia, regardless of delivery method.6

glycemic control

Insight Before Insulin for Informed Diabetes Treatment Decisions

The unique value of continuous information, raising glucose awareness7 and lowering A1C, regardless of insulin delivery method,6 makes a strong case for prescribing a Dexcom Continuous Glucose Monitoring (CGM) System before pump therapy.

The Cost of Poor Diabetes Control

CGM delivers many of the benefits of complex care management programs, but with greater cost transparency.

Rethink Care Management

Lowering A1C can unlock clinical and financial benefits.


Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The diamond randomized clinical trial. JAMA. 2017;317(4):371-378. doi:10.1001/jama.2016.19975.


Nathan D, Cleary PA, Backlund JC, Genuth SM, et al. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. N Engl J Med 2005;353:2643-53.


Nathan et al. The Diabetes Control and Complications Trial Research Group - The Eect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N Engl J Med. Vol 329 No. 14. 1993.


Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: The gold randomized clinical trial. JAMA. 2017;317(4):379-387.


Rodbard D, Bailey T, Jovanovic L, Zisser H, Kaplan R, Garg SK. Improved quality of glycemic control and reduced glycemic variability with use of continuous glucose monitoring. Diabetes Technol Ther. 2009 Nov;11(11).727-23. 


Šoupal J, Petruželková L, Flekač M, et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technol Ther. 2016;18(9):532-538.


Pettus J, Price DA, Edelman SV. How Patients with Type 1 Diabetes Translate Continuous Glucose Monitoring Data into Diabetes Management Decisions. Endocr Pract. 2015;:1-25.